INO logo

INOVIO PHARMACEUTICALS INC

INONASDAQ
๐Ÿ† #3800 by market capEarnings Aug 12US Equity
$0.76โ–ผ $0.01 (โˆ’0.93%)
Live
1hโ–ผ 0.1%
24hโ–ผ 0.9%
7dโ–ฒ 12.6%
14dโ–ผ 27.4%
30dโ–ผ 34.9%
1yโ–ผ 48.4%
๐ŸฆMarket Cap
$52M
Small Cap
๐Ÿ“ˆRevenue Growth (YoY)
-70.0%
Declining
๐Ÿ“ŠGross Margin
0.0%
Thin
๐Ÿ’ตFCF Margin
0.0%
Thin
โš–๏ธP/S Ratio
0.0x
Cheap
Otter Score
61
Fair

Trading Snapshot

Day Range
$0.75 โ€“ $0.77
52-Week Range
$0.56 โ€“ $2.98
Volume
$2.62B
Avg Volume
$2.11B
Shares Outstanding
69.1M
Next Earnings
Sep 1, 2026

Fundamentals Snapshot

Annual Revenue
$65,343
Last Q Revenue
$18,086
P/E Ratio
-0.4
P/S Ratio
0.0x
EPS (TTM)
$-1.23
Dividend Yield
0.00%

Why Investors Own INO

  • โœ“High-growth profile โ€” revenue up +47.1% YoY with expanding US Equity exposure.
  • โœ“Healthy economics โ€” 66% gross margin and 10% free-cash-flow margin.
  • โœ“New products and segments could unlock additional revenue streams.
โš ๏ธ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)
$65,343โ–ฒ +45.6% YoY
Gross Margin (TTM)
66.0%โ–ฒ +4.4% YoY
Operating Income (TTM)
$8,821โ–ฒ +45.6% YoY
Free Cash Flow (TTM)
$6,338โ–ฒ +45.6% YoY

About INOVIO PHARMACEUTICALS INC

Inovio Pharmaceuticals, Inc. is a biotechnology firm dedicated to the research, development, and market introduction of DNA-based treatments. Its core mission is to prevent and cure illnesses associated with human papillomavirus (HPV), various types of cancer, and infectious diseases. The company's advanced DNA medicine platform utilizes meticulously engineered SynCon sequences to precisely identify and optimize the genetic blueprint of a target antigen. This innovative approach is supported by its CELLECTRA smart device technology, which efficiently delivers the DNA plasmids. Inovio is actively engaged in and planning clinical trials for its DNA medicines across a wide array of conditions. These include HPV-related precancerous lesions, such as cervical, vulvar, and anal dysplasia; HPV-driven cancers affecting areas like the head and neck, cervix, anus, penis, vulva, and vagina; and other HPV-associated disorders like recurrent respiratory papillomatosis. Beyond HPV, its pipeline addresses glioblastoma multiforme, prostate cancer, and a range of infectious diseases, including HIV, Ebola, Middle East Respiratory Syndrome (MERS), and Lassa fever. The company benefits from a vast network of collaborators and partners, encompassing prominent academic institutions, government agencies, non-profit foundations, and pharmaceutical corporations. Key examples include AstraZeneca, The Bill & Melinda Gates Foundation, the Coalition for Epidemic Preparedness Innovations (CEPI), the Defense Advanced Research Projects Agency (DARPA), the National Institutes of Health, Regeneron Pharmaceuticals, and the University of Pennsylvania. Significant partnerships also involve an agreement with Richter-Helm BioLogics GmbH & Co. KG to further develop the investigational COVID-19 DNA vaccine INO-4800, alongside a strategic alliance with the International Vaccine Institute and Seoul National University Hospital. Established in 1979, Inovio Pharmaceuticals is headquartered in Plymouth Meeting, Pennsylvania.

๐Ÿฆฆ

Otter Score Breakdown

โ“˜
๐Ÿ’ŽQualityโ˜…โ˜…โ˜…โ˜…โ˜…
๐Ÿš€Growthโ˜…โ˜…โ˜…โ˜…โ˜…
โš–๏ธValuationโ˜…โ˜…โ˜…โ˜…โ˜…
โšกMomentumโ˜…โ˜…โ˜…โ˜…โ˜…
Overall Score
Fair
61/100

Analyst Ratings

โ“˜
Consensus
Buy
8 analysts
Strong Buy1
Buy4
Hold3
Sell0
Strong Sell0
Ratings as of Aug 2026

Latest News & Updates

๐Ÿš€
Benzingaยท9d ago

Piper Sandler Reiterates Overweight on Inovio Pharmaceuticals, Lowers Price Target to $4

Piper Sandler analyst Edward Tenthoff reiterates Inovio Pharmaceuticals (NASDAQ:INO) with a Overweight and lowers the price target from $6 to $4.

ChartMillยท12d ago

Here are the top movers in Thursday's session.

Wondering how the US markets performed one hour before the close of the markets on Thursday? Discover the movers and shakers of today's session in our comprehensive analysis.

ChartMillยท12d ago

Let's uncover which stocks are experiencing notable gaps during today's session.

The session on Thursday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session.

Benzingaยท13d ago

12 Health Care Stocks Moving In Thursday's Intraday Session

Gainers Nuwellis (NASDAQ:NUWE) stock moved upwards by 123.7% to $4.23 during Thursday's regular session. GlucoTrack (NASDAQ:GCTK) shares moved upwards by 79.85% to $0.51. The company's market cap stands at

ChartMillยท13d ago

Stay updated with the stocks that are on the move in today's pre-market session.

Before the opening bell on Thursday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session.

Benzingaยท13d ago

Nasdaq Surges Over 600 Points; Microsoft Shares Jump After Upbeat Q4 Results

US stocks rise with Nasdaq up 600 points, Dow up 0.69% and S&P 500 up 1.29%. Tech shares up 5%, communication services down 3.3%. Microsoft jumps 15% after strong earnings.